The agency expanded approval for semaglutide this month. Here is what changes for prescribers, insurers, and the people who actually take it.
The first direct comparison trial is in. The numbers favor tirzepatide on weight loss — but the story is more nuanced than the headlines.
A 17,000-patient study quietly reshaped how cardiologists think about weight, inflammation, and risk. We read the protocol so you don't have to.
The internet has elevated easy-pace endurance work to near-mythical status. The research is solid — but the protocol most people follow is not.
A pooled analysis of 90,000 patients confirms what nephrologists have suspected: this drug class is doing more than lowering glucose.
Forget the 75-day challenge. The research consistently points to small, repeatable behaviors — and most of them do not happen in a gym.
Compounded semaglutide kept many patients medicated through the shortage. As branded supply returns, the legal and safety landscape is shifting fast.
Manufacturing GLP-1 medications is harder than it looks. A look at the bottlenecks driving pharmacy shortages into the second half of 2026.
The agency expanded approval for semaglutide this month. Here is what changes for prescribers, insurers, and the people who actually take it.
The first direct comparison trial is in. The numbers favor tirzepatide on weight loss — but the story is more nuanced than the headlines.
Compounded semaglutide kept many patients medicated through the shortage. As branded supply returns, the legal and safety landscape is shifting fast.
Manufacturing GLP-1 medications is harder than it looks. A look at the bottlenecks driving pharmacy shortages into the second half of 2026.
Rapid weight loss takes lean tissue along with fat. New research clarifies how much, and what to do about it.
A 17,000-patient study quietly reshaped how cardiologists think about weight, inflammation, and risk. We read the protocol so you don't have to.
A pooled analysis of 90,000 patients confirms what nephrologists have suspected: this drug class is doing more than lowering glucose.
A short guide to spotting the difference between a headline-worthy result and one that should not change your weekend plans.
Sixty-two trials, 6,400 participants, and a more sober picture than the bestseller list suggests.
Machine-learning systems now match patients to trials in days, not months. The early results are promising. The blind spots are worth naming.
The internet has elevated easy-pace endurance work to near-mythical status. The research is solid — but the protocol most people follow is not.
Forget the 75-day challenge. The research consistently points to small, repeatable behaviors — and most of them do not happen in a gym.
The RDA was set for survival, not for thriving. Newer evidence — and a generation of stronger older adults — argues for higher targets.
Hours in bed correlate with everything from strength gains to injury risk. The good news: most of the upside comes from boringly basic changes.
Wearables present HRV as a daily verdict on your readiness. The actual physiology is more interesting — and more forgiving.